Shaw Barbara Ramsay, Moussa Laura, Sharaf Mariam, Cheek Marcus, Dobrikov Mikhail
Department of Chemistry, Duke University, 124 Science Drive, Durham, NC 27708-0346, USA.
Nucleic Acids Symp Ser (Oxf). 2008(52):655-6. doi: 10.1093/nass/nrn331.
There is a need for novel, effective, and cell- and gene-specific therapeutics for cancer. Modified oligonucleotides can be used to modulate specifically and potently the expression of several genes that are upregulated in breast and prostate cancer and have been found to be causal to the tumor phenotype. Synergistic downregulation of these genes may be a potent therapeutic intervention. We are investigating the use of boranophosphate (BP) analogues of RNA as promising candidates for enhancing the potential of three relatively new, gene-specific, anticancer strategies: (1) Tumor-targeted borane siRNA against a combination of genes that control metabolism and transduction; (2) Tumor-specific modified aptamers against prostate specific membrane antigen (PSMA) and ERB2 in breast cancer as delivery agents; and (3) Cancer cell obliteration by cell-specific radiation therapy: Boron-Neutron-Capture-Therapy.
癌症需要新型、有效且具有细胞和基因特异性的治疗方法。修饰的寡核苷酸可用于特异性且有效地调节在乳腺癌和前列腺癌中上调且已被发现与肿瘤表型相关的多个基因的表达。这些基因的协同下调可能是一种有效的治疗干预措施。我们正在研究使用RNA的硼磷酸盐（BP）类似物，作为增强三种相对较新的、基因特异性抗癌策略潜力的有前景的候选物：（1）针对控制代谢和转导的基因组合的肿瘤靶向硼烷siRNA；（2）针对前列腺特异性膜抗原（PSMA）和乳腺癌中的ERB2的肿瘤特异性修饰适体作为递送剂；（3）通过细胞特异性放射疗法消除癌细胞：硼中子俘获疗法。
